Publications
March 28, 2024
Phase 1 trial shows autologous CD5.CAR T cells are safe and effective in r/r T-cell lymphoma with a 44% overall response rate, promising advances in T-cell malignancy treatment.
June 2, 2023
We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.
November 13, 2019
We describe a Phase I dose escalation study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or refractory (r/r) T-cell leukemia and lymphoma.
News
February 22, 2024
Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years
A CAR T cell therapy for T cell lymphoma showed promise in a Phase I clinical trial, Baylor College of Medicine scientists said.
November 17, 2023
March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials
March Biosciences received a $13.4 million grant award from CPRIT to support continued clinical development of MB-105 CD5 CAR-T for T-cell lymphoma
November 9, 2023
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences
The Cancer Focus Fund LP invested $4.8 million into a cell therapy company that has already tapped some of Houston’s growing life sciences resources.